Navigation Links
Vivakor Divisions Continue to Demonstrate Independent Growth
Date:12/15/2009

CORALVILLE, Iowa, Dec. 15 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) Several of Vivakor's divisions have reported strong performance in 2009. Vivakor is a transdisciplinary hub of research and development with divisional spokes developing multiple products and technologies for market. Vivakor's R&D Product Pipeline strategy is anchored to the concept of licensing and strategic partnering. From idea inception, Vivakor's R&D efforts target commercialization and product-specific exit strategies to increase revenue potential from each new Vivakor technology. With a multi-million dollar purchase commitment in its nutraceutical division, new market opportunities and distribution agreements for its VivaThermic division's cryovials and continued growth in optics and MRI technology, the continued success of each of these divisions is seen as strong validation for the business model.

Executive Chairman Matt Nicosia was quoted: "Vivakor has made great strides in 2009. With the recent successes in several of our divisions, we are certain that the value proposition of our company will continue to increase. We expect continued success on several tracks and expect 2010 to be our most successful in terms of commercial success and equity value perspectives. Our greatest strength is from our diversity."

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact:

Vivakor Investor Relations

c/o IME Advisors

(888) 648-8485

SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
2. Vivakor Announces New Acquisition Strategy
3. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
4. Reported Use of AMAGs Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are On the Verge of Use
5. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
6. instaCare Corp. Continues Turnaround, Reports 58% Revenues Increase for First Three Quarters
7. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
8. The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018
9. Health Care Retail Clinics Continue Gradual Expansion Through 2012: Deloitte Center for Health Solutions Report
10. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
11. Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):